March 29, 2024 Breaking Ground in Alzheimer’s Diagnosis: Simoa® p-Tau 217 Blood Test Receives FDA Breakthrough Device Designation read more
March 14, 2024 Advancing Alzheimer’s Disease Pathology Detection with Simoa® ALZpath p-Tau217 Assay read more
February 15, 2024 Advances in Blood-Based Biomarkers for Alzheimer’s and Parkinson’s Diseases read more
February 13, 2024 CSF p-Tau 205 Emerges as a Biomarker of Tau Pathology in Alzheimer’s Disease read more
January 30, 2024 Approaches to Assay Characterization and Validation: Part 1- Limit of Detection and Lower Limit of Quantitation read more
January 10, 2024 Simoa® Advantage PLUS: Improving Precision, Consistency, and Sustainability in Biomarker Research read more